HK1215392A1 - 用於对抗黑色素瘤细胞的飞燕草素 - Google Patents

用於对抗黑色素瘤细胞的飞燕草素 Download PDF

Info

Publication number
HK1215392A1
HK1215392A1 HK16103394.8A HK16103394A HK1215392A1 HK 1215392 A1 HK1215392 A1 HK 1215392A1 HK 16103394 A HK16103394 A HK 16103394A HK 1215392 A1 HK1215392 A1 HK 1215392A1
Authority
HK
Hong Kong
Prior art keywords
delphinidin
cells
sbe
cell
composition
Prior art date
Application number
HK16103394.8A
Other languages
English (en)
Chinese (zh)
Inventor
諾伯特‧若維爾
诺伯特‧若维尔
延斯‧布若斯凱特
延斯‧布若斯凯特
Original Assignee
赛博尔泰克股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赛博尔泰克股份公司 filed Critical 赛博尔泰克股份公司
Publication of HK1215392A1 publication Critical patent/HK1215392A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
HK16103394.8A 2012-12-11 2013-11-28 用於对抗黑色素瘤细胞的飞燕草素 HK1215392A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102012222777.6 2012-12-11
DE102012222777 2012-12-11
EP13150909 2013-01-11
EP13150909.3 2013-01-11
PCT/EP2013/074991 WO2014090586A1 (de) 2012-12-11 2013-11-28 Delphinidin zur bekämpfung von melanomzellen

Publications (1)

Publication Number Publication Date
HK1215392A1 true HK1215392A1 (zh) 2016-08-26

Family

ID=49679524

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103394.8A HK1215392A1 (zh) 2012-12-11 2013-11-28 用於对抗黑色素瘤细胞的飞燕草素

Country Status (8)

Country Link
US (2) US9511047B2 (https=)
EP (2) EP2931286B1 (https=)
JP (2) JP6234476B2 (https=)
KR (2) KR102164174B1 (https=)
CN (2) CN104936601A (https=)
CA (2) CA2893883A1 (https=)
HK (1) HK1215392A1 (https=)
WO (2) WO2014090586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014075935A1 (de) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
CN104936601A (zh) 2012-12-11 2015-09-23 赛博尔泰克股份公司 用于对抗黑色素瘤细胞的飞燕草素

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5946228A (ja) 1982-09-08 1984-03-15 Zeria Shinyaku Kogyo Kk 生物学的に活性な有機化合物の水溶性及びリンパ移行性薬剤の製造方法
HU199444B (en) 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
GB8907008D0 (en) 1989-03-28 1989-05-10 Inverni Della Beffa Spa Intermediates useful for the synthesis for delphinidin chloride
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
DK1666591T3 (da) * 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
GB2307176A (en) 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
JP4101346B2 (ja) 1998-02-18 2008-06-18 ダイセル化学工業株式会社 酸化触媒系及びそれを用いた酸化方法
EP1067942A1 (en) 1998-02-23 2001-01-17 Cyclops, EHF. High-energy cyclodextrin complexes
US6699849B1 (en) 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
GB2350297A (en) 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
AU6527300A (en) 1999-08-11 2001-03-05 Josef Pitha Potentiation of inclusion complex formation of cyclodextrin derivatives
AU7937500A (en) 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
CA2421954C (en) * 2000-09-12 2007-02-06 Meiji Seika Kaisha, Ltd. Process for producing purified anthocyanin and crystalline anthocyanin
EP1383445A4 (en) 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2003171274A (ja) 2001-12-07 2003-06-17 Tomihiko Higuchi 薬剤耐性菌感染症治療のための医薬組成物および消毒剤
WO2003063824A2 (en) 2002-02-01 2003-08-07 Shimoda Biotech (Pty) Ltd Pharmaceutical composition
JP2004238336A (ja) * 2003-02-07 2004-08-26 Sanei Gen Ffi Inc 水易溶性包接フラボノイド類の製造方法
US20050013880A1 (en) * 2003-03-06 2005-01-20 Magnuson Bernadene Ann Anthocyanin-rich compositions and methods for inhibiting cancer cell growth
WO2004087100A2 (en) 2003-03-28 2004-10-14 Ivax Corporation Cladribine formulations for improved oral and transmucosal delivery
KR20060130646A (ko) 2004-01-14 2006-12-19 가부시키가이샤 오츠까 세이야꾸 고죠 프로포폴 함유 지방 유제
CN1317961C (zh) 2004-03-25 2007-05-30 吴朝琴 冻干草莓加工工艺
CN100342026C (zh) * 2004-05-13 2007-10-10 深圳新鹏生物工程有限公司 重组人可溶性肿瘤坏死因子相关凋亡诱导配体制备方法
WO2006076387A2 (en) * 2005-01-11 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Cyanidin-3-glucoside as an anti-neoplastic agent
DE102005017775A1 (de) 2005-04-13 2006-10-19 Schering Ag Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins
KR100733913B1 (ko) * 2005-08-30 2007-07-02 한국화학연구원 안토시아닌을 포함하는 뇌세포 보호제와 뇌경색 및 뇌졸중예방 또는 치료제
US7645748B2 (en) * 2006-04-03 2010-01-12 Forbes Medi-Tech Inc. Sterol/stanol phosphorylnitroderivatives and use thereof
EP2099408B1 (en) 2006-11-28 2016-10-05 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
KR100756656B1 (ko) 2006-12-12 2007-09-10 한국화학연구원 안토시아닌을 포함하는 뇌경색 또는 뇌졸중 예방 및 개선용건강식품
KR100880876B1 (ko) 2007-04-11 2009-01-30 경상대학교산학협력단 검정콩 껍질로부터 추출한 안토시아닌을 함유하는 피판이나조직의 허혈-재관류 손상의 예방 또는 치료용 의약 조성물
US20090082400A1 (en) * 2007-07-31 2009-03-26 Ving Lee Soluble pyrone analogs methods and compositions
JP5574600B2 (ja) 2007-12-17 2014-08-20 日本製薬工業株式会社 吸収性骨疾患の予防・治療剤
EP2106786A1 (de) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010110328A1 (ja) 2009-03-25 2010-09-30 三栄源エフ・エフ・アイ株式会社 水易溶性イソクエルシトリン組成物
EP2437770A4 (en) 2009-06-05 2013-11-06 Univ Colorado Regents ANTIMICROBIAL PEPTIDES
EP2344154B1 (en) 2009-10-21 2016-12-07 Maqui New Life S.A. Compositions that include anthocyanidins and methods of use
EP2345427A1 (de) 2010-01-14 2011-07-20 SapioTec GmbH Flurankomplex
JP2013521796A (ja) 2010-03-13 2013-06-13 イーストポンド・ラボラトリーズ・リミテッド 脂肪結合性組成物
DE102010042615A1 (de) 2010-10-19 2012-04-19 Wacker Chemie Ag 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel
CA2822995C (en) 2010-12-31 2021-05-11 Eastpond Laboratories Limited Cellular hydration compositions containing cyclodextrins
EP2484350B1 (de) 2011-02-04 2016-04-20 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung, enthaltend einen Komplex eines Propofolsalzes mit einem Cyclodextrin
KR101905937B1 (ko) 2012-03-30 2018-10-08 자피오텍 게엠베하 안토시아니딘 복합체
ES2620080T3 (es) 2012-03-30 2017-06-27 Sapiotec Gmbh Uso de delfinidina contra Staphylococcus aureus
WO2014060548A1 (de) 2012-10-17 2014-04-24 Sapiotec Gmbh Anthocyanidin-komplex zur behandlung von multiplem myelom
WO2014075935A1 (de) 2012-11-15 2014-05-22 Sapiotec Gmbh Delphinidinkomplex als antiphlogistischer oder immunsuppressiver wirkstoff
CN104936601A (zh) 2012-12-11 2015-09-23 赛博尔泰克股份公司 用于对抗黑色素瘤细胞的飞燕草素
EP2913050A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
EP2913366A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Anthocyanidin-Komplex

Also Published As

Publication number Publication date
HK1216229A1 (zh) 2016-10-28
KR102164174B1 (ko) 2020-10-12
EP2931287A1 (de) 2015-10-21
US9949947B2 (en) 2018-04-24
CA2893881A1 (en) 2014-06-19
EP2931287B1 (de) 2017-10-04
JP6234475B2 (ja) 2017-11-22
WO2014090586A1 (de) 2014-06-19
WO2014090583A1 (de) 2014-06-19
EP2931286A1 (de) 2015-10-21
JP2016502984A (ja) 2016-02-01
CA2893881C (en) 2020-09-22
CA2893883A1 (en) 2014-06-19
CN104936601A (zh) 2015-09-23
KR20150107742A (ko) 2015-09-23
US20150320719A1 (en) 2015-11-12
US9511047B2 (en) 2016-12-06
US20150328336A1 (en) 2015-11-19
CN104918622A (zh) 2015-09-16
JP6234476B2 (ja) 2017-11-22
JP2016502985A (ja) 2016-02-01
EP2931286B1 (de) 2017-10-04
KR20150107741A (ko) 2015-09-23

Similar Documents

Publication Publication Date Title
Fan et al. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition
Guerrero et al. Curcumin-loaded nanoemulsion: A new safe and effective formulation to prevent tumor reincidence and metastasis
Kim et al. Synergistic oxygen generation and reactive oxygen species scavenging by manganese ferrite/ceria co-decorated nanoparticles for rheumatoid arthritis treatment
Onodera et al. Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-β-cyclodextrin
Yuan et al. Highly sensitive imaging of tumor metastasis based on the targeting and polarization of M2-like macrophages
Zhong et al. Redox dual-responsive dendrimeric nanoparticles for mutually synergistic chemo-photodynamic therapy to overcome drug resistance
Xiao et al. Engineering cannabidiol synergistic carbon monoxide nanocomplexes to enhance cancer therapy via excessive autophagy
Zhang et al. Dual functional mesoporous silicon nanoparticles enhance the radiosensitivity of VPA in glioblastoma
JP5663741B2 (ja) アミノ酸抱合シアノアクリレートポリマー粒子
Srinivasulu et al. Gold nanocluster based nanocomposites for combinatorial antibacterial therapy for eradicating biofilm forming pathogens
Chen et al. Bufotalin loaded biomimetic nanodrug for combined chemo/photodynamic therapy of cancer
Zhou et al. Development and investigation of dual potent anticancer drug-loaded nanoparticles for the treatment of lung cancer therapy
Wu et al. Fluorescent hyaluronic acid nanoprodrug: A tumor-activated autophagy inhibitor for synergistic cancer therapy
Azmoonfar et al. Radioprotection and enhanced efficacy by curcumin-loaded chitosan nanoparticles in mitigating radiation-induced liver injury
HK1215392A1 (zh) 用於对抗黑色素瘤细胞的飞燕草素
Itzhaki et al. Tumor‐Targeted Poly (ArgGlyAsp) Nanocapsules for Personalized Cancer Therapy–In Vivo Study
Feng et al. Combining photodynamic therapy and ATM inhibition using modified bovine serum albumin: A co-delivery nano platform for eliciting pyroptosis and apoptosis to fuel TNBC therapy
CN109893662B (zh) 抑制Mfsd2a的载前药脑转移瘤靶向给药系统的制备方法及应用
CN104780925A (zh) 用于治疗多发性骨髓瘤的花青素络合物
Eltahan et al. NVP-BEZ235/Chlorin-e6 co-loaded nanoparticles ablate breast cancer by biochemical and photodynamic synergistic effects
Lin et al. Postoperatively injected gel with sequential delivery of platinum agents to synergize with radiotherapy for suppressing high-grade glioma relapse
Mehata et al. Fluorescent Calcium Nanocluster-Driven Theranostic Nanoplatforms for Advanced Imaging and Therapy in Breast Tumor
Tunikowska et al. Maczy nska
HK1216229B (en) Delphinidin for combating melanoma cells